The median treatment duration for both groups was 12 months, with a median prophylactic dose of glycopegylated EHL FVIII at 50 IU/kg/week in hemophilia A and glycopegylated EHL FIX at 40 IU/kg every 21 days in hemophilia B. Common bleeding sites in hemophilia A included the right knee (21.81%), right ankle (10.90%), and right elbow (10.90%), whereas hemophilia B patients experienced frequent bleeding in both knees (25%) right knee (16.66%), left knee (16.66%), and left ankle (16.66%) (Tables 1-2). The gene discussed is F8; the disease is hemophilia B.